注册号: Registration number: |
ChiCTR2000033050 |
最近更新日期: Date of Last Refreshed on: |
2020-05-19 |
注册时间: Date of Registration: |
2020-05-18 |
注册号状态: |
预注册 |
Registration Status: |
Prospective registration |
注册题目: |
大剂量静脉注射维生素C治疗新型冠状病毒肺炎(COVID-19)普通型的回顾性前后对照单中心临床研究 |
Public title: |
Effect of high dose intravenous vitamin C on moderate novel coronavirus pneumonia (COVID-19) patients: a medical records based retrospective study |
注册题目简写: |
|
English Acronym: |
|
研究课题的正式科学名称: |
大剂量静脉注射维生素C治疗新型冠状病毒肺炎(COVID-19)普通型的回顾性前后对照单中心临床研究 |
Scientific title: |
Effect of high dose intravenous vitamin C on moderate novel coronavirus pneumonia (COVID-19) patients: a medical records based retrospective study |
研究课题代号(代码): Study subject ID: |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
申请注册联系人: |
赵冰 |
研究负责人: |
毛恩强 |
Applicant: |
Bing Zhao |
Study leader: |
Enqiang Mao |
申请注册联系人电话: Applicant telephone: |
+86 18017117871 |
研究负责人电话: Study leader's telephone: |
+86 13501747906 |
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
申请注册联系人电子邮件: Applicant E-mail: |
zhaobing124@163.com |
研究负责人电子邮件: Study leader's E-mail: |
maoeq@yeah.net |
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
申请注册联系人通讯地址: |
上海市黄浦区瑞金二路197号瑞金医院 |
研究负责人通讯地址: |
上海市黄浦区瑞金二路197号瑞金医院 |
Applicant address: |
197 Second Ruijin Road, Huangpu District, Shanghai, China |
Study leader's address: |
197 Second Ruijin Road, Huangpu District, Shanghai, China |
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
申请人所在单位: |
上海交通大学医学院附属瑞金医院 |
||
Applicant's institution: |
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine |
是否获伦理委员会批准: |
否 |
||
Approved by ethic committee: |
NO |
||
伦理委员会批件文号: Approved No. of ethic committee: |
伦理委员会批件附件: Approved file of Ethical Committee: |
||
批准本研究的伦理委员会名称: |
|
||
Name of the ethic committee: |
|
||
伦理委员会批准日期: Date of approved by ethic committee: |
2013-08-26 | ||
伦理委员会联系人: |
|
||
Contact Name of the ethic committee: |
|
||
伦理委员会联系地址: |
|
||
Contact Address of the ethic committee: |
|
||
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
研究实施负责(组长)单位: |
上海交通大学医学院附属瑞金医院 |
||||||||||||||||||||||
Primary sponsor: |
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine |
||||||||||||||||||||||
研究实施负责(组长)单位地址: |
上海市黄浦区瑞金二路197号瑞金医院 |
||||||||||||||||||||||
Primary sponsor's address: |
197 Second Ruijin Road, Huangpu District, Shanghai, China |
||||||||||||||||||||||
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
经费或物资来源: |
上海市科委第二批应急科技攻关项目 |
||||||||||||||||||||||
Source(s) of funding: |
The second batch of emergency science and technology projects of Shanghai Science and Technology Commission |
||||||||||||||||||||||
研究疾病: |
新型冠状病毒肺炎(COVID-19) |
||||||||||||||||||||||
Target disease: |
Novel Coronavirus Pneumonia (COVID-19) |
||||||||||||||||||||||
研究疾病代码: |
|
||||||||||||||||||||||
Target disease code: |
|
||||||||||||||||||||||
研究类型: |
观察性研究 |
||||||||||||||||||||||
Study type: |
Observational study |
||||||||||||||||||||||
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
Study phase: |
Retrospective study |
||||||||||||||||||||||
研究目的: |
HDIVC对COVID-19患者炎症反应相关指标的改善作用。 |
||||||||||||||||||||||
Objectives of Study: |
The improvement effection in the inflammation-related indexes of HDIVC to patients with COVID-19. |
||||||||||||||||||||||
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
Study design: |
Non randomized control |
||||||||||||||||||||||
纳入标准: |
1)入院时诊断为新冠肺炎,严重程度分级为重型及危重型,具体分级标准参考国家卫生健康办公厅发布的新型冠状病毒肺炎诊疗方案(第六版),具体为:具有发热、呼吸道等症状,影像学检查可见肺炎表现; 2)年龄>18岁。 |
||||||||||||||||||||||
Inclusion criteria |
1. Patients who was diagnosed with COVID-19 pneumonia with severe and critical severity. Diagnosis were performed according to World Health Organization interim guidance11. 2. Aged > 18 years old. |
||||||||||||||||||||||
排除标准: |
1)在治疗期间合并肿瘤发生; 2)处于怀孕或哺乳期; 3) 在本研究时间范围内使用其他试验药物治疗。 |
||||||||||||||||||||||
Exclusion criteria: |
1. During the treatment, the tumor occurred; 2. During pregnancy or lactation; 3. Under the treatment of other testing drug. |
研究实施时间: Study execute time: |
从From2020-01-01至To 2020-06-30 |
征募观察对象时间: Recruiting time: |
从From2020-05-04至To 2020-06-30 |
干预措施: Interventions: |
|
研究实施地点: Countries of recruitment and research settings: |
|
测量指标: Outcomes: |
|